Q-omics provides the consensus-scored TSPYL6 profile across patient tissues and cancer cell-line models. TSPYL6 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TSPYL6 is differentially expressed in 8, with the highest sampling consensus in UCEC. Additionally, TSPYL6 RNA expression shows 15,437 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, UCEC, and TGCT as cancer lineages where TSPYL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPYL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPYL6 survival associations across molecular data types. TSPYL6 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPYL6 RNA expression–survival associations across cancer types. High TSPYL6 expression shows unfavorable associations in ACC, CHOL, KIRC and PAAD, but favorable associations in SCLC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify ACC as the clearest survival context for TSPYL6 RNA expression.
This table summarizes TSPYL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for TSPYL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPYL6 shows lower tumor expression in UCEC, BRCA and LUSC and higher tumor expression in ESCA, CHOL and COAD. The UCEC box plot shows higher TSPYL6 RNA expression in normal versus tumor tissue (log2 FC = −0.063, t-test p = .044).
This table shows molecular features associated with TSPYL6 in patient tissues and cancer cell lines. In patient samples, TSPYL6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPYL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
